Skip to Content
Find More Like This
Return to Search

Outcome prediction and risk classification in childhood leukemia

United States Patent Application

20090203588
A1
View the Complete Application at the US Patent & Trademark Office
Sandia National Laboratories - Visit the Intellectual Property Management and Licensing Website
Genes and gene expression profiles useful for predicting outcome, risk classification, cytogenetics and/or etiology in pediatric acute lymphoblastic leukemia (ALL). OPAL1 is a novel gene associated with outcome and, along with other newly identified genes, represent a novel therapeutic targets.
Willman, Cheryl L. (Albuquerque, NM), Helman, Paul (Albuquerque, NM), Veroff, Robert (Albuquerque, NM), Mosquera-Caro, Monica (Albuquerque, NM), Davidson, George S. (Albuquerque, NM), Martin, Shawn B. (Albuquerque, NM), Atlas, Susan R. (Albuquerque, NM), Andries, Erik (Rio Rancho, NM), Kang, Huining (Albuquerque, NM), Shuster, Jonathan J. (Gainesville, FL), Wang, Xuefei (Albuquerque, NM), Harvey, Richard C. (Placitas, NM), Haaland, David M. (Albuquerque, NM), Potter, Jeffrey W. (Albuquerque, NM)
STC.UNM.
11/ 811,436
June 8, 2007
STATEMENT OF GOVERNMENT RIGHTS [0002] This invention was made with government support under a grant from the National Institutes of Health (National Cancer Institute), Grant No. NIH NCI U01 CA88361; and under a contract from the Department of Energy, Contract No. DE-AC04-94AL85000. The U.S. Government has certain rights in this invention.